Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life’s Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for Veterans
VANCOUVER, BC / ACCESSWIRE / December 3, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce a partnership with the Westwood Institute (the “Institute”), a veterans mental health-focused non-profit founded by Dr. Marvin Westwood.
The Institute’s mission is to expand on Dr. Westwood’s work with veterans and empower clinicians around the world with evidence-based interventions and clinical training. Group counselling, trauma treatment and emerging therapies are key pillars of the Institute’s approach.
Dr. Westwood is Professor Emeritus of Counselling Psychology, at the University of British Columbia’s (UBC) Faculty of Education. Over his 25-year career at UBC, Dr. Westwood has trained thousands of psychologists and counsellors from across the world. His major areas of teaching and research focused on the development, teaching and delivery of group-based approaches for counselling clients, and men’s psychological health.
“The Havn Life team is elated to have access to the depth of knowledge and experience that Dr. Westwood brings to helping veterans with their mental health” said Susan Chappelle, EVP of Research and Development. “The partnership with the Westwood Institute will provide extensive expertise to Havn Life for combining therapy and psychedelic intervention for veterans.”
Dr. Westwood developed the University of British Columbia Veterans Transition Program, a group counselling program for veterans, to date the program has helped thousands of veterans. Dr. Westwood’s work promoted recovery from war-related stress injuries for which he received both the Queen’s Golden and Diamond Jubilee Medals in 2005 and 2013. In 2012 he established the Centre for Group Counselling & Trauma-focused training clinicians around the world with the latest group counselling techniques.
Dr. Westwood remarked: “It is exciting to see Havn Life taking leadership with its research plans. Trauma is a major problem in our society and new approaches to treating trauma are desperately needed. Research into psychedelics such as psilocybin should take a holistic approach. By combining psychedelic intervention with existing evidence-based counselling treatments we can develop best practices for patients dealing with a wide array of traumas.”
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.
Investor Relations: firstname.lastname@example.org, 604 687 7130
Media: email@example.com, 778 238 6096
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.